Table 1 Comparison of clinical and molecular features of childhood intermediate-risk AML and CK-AML

Age (years)

2.5 (0.3–15.2)

5.0 (0.3–14.8)

0.031

Male/female

19/15

43/39

n.s

WBC (10¹²/L)

21.83 (0.88–249.96)

20.02 (0.85–389.96)

n.s

% blast in bone marrow

71 (20–95)

69 (16–97)

n.s

Gene mutations [% (no./total)]

  CEBPA

6 (2/33)

14 (10/74)

n.s

  FLT3/ITD

6 (2/33)

0 (0/79)

n.s

   WT1

13 (4/32)

13 (9/68)

n.s

   IDH1

6 (2/33)

4 (3/74)

n.s

   KRAS

3 (1/33)

5 (4/76)

n.s

   NRAS

3 (1/33)

18 (14/80)

0.079

   KIT

0 (0/33)

5 (4/76)

n.s

   IDH2

0 (0/33)

4 (3/78)

n.s

   GATA2

3 (1/31)

1 (1/69)

n.s

   Others^†

0

0

Outcomes (%)

   Complete remission rate

60 (12/20)

83 (48/58)

0.076

   Relapse

58 (7/12)

38 (18/48)

n.s

   Relapse and failure to CR

60 (12/20)

48 (28/58)

n.s